Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral PG-116800 Following a Heart Attack
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2014
Price :
$35
*
At a glance
- Drugs PG 116800 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Procter & Gamble
- 26 May 2014 New trial record